Schrodinger
SDGR
27.29
-1.61
-5.57%
Schrodinger
US · SDGR
#2667 by market cap
Listed 2020
27.29
-1.61
-5.57%
Live - 5344 symbols - heartbeat 66s ago
· 2026-10-08 06:53
Pre-market
26.80
-1.80%
After-hours
27.20
-0.33%
Overnight
27.29
0.00%
- Market cap
- 2.04B
- P/E (TTM)i
- -37.38
- P/Bi
- 6.21
- EPSi
- -1.41
- Div yieldi
- 0.00%
- 52W posi
- 72%
Reader sentiment
Are you bullish or bearish on SDGR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.31, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +23.29% YoY
Margins
- Gross margin
- 55.74%
- Operating margin
- -65.23%
- Net margin
- -40.36%
Key ratios & quality
- Altman Z-Scorei
- 2.31
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 66.64M | 85.54M | 108.10M | 137.93M | 180.96M | 216.67M | 207.54M | 255.87M |
| Gross profit | 42.94M | 49.09M | 63.47M | 65.62M | 101.02M | 140.69M | 132.08M | 142.61M |
| Selling & admin expenses | 36.38M | 48.40M | 59.69M | 86.16M | 121.47M | 136.37M | 139.59M | 136.37M |
| Research & development | 34.52M | 39.40M | 64.70M | 90.90M | 126.37M | 181.77M | 201.79M | 173.14M |
| Operating profit | -27.97M | -38.72M | -60.92M | -111.44M | -146.82M | -177.45M | -209.30M | -166.90M |
| Pretax profit | -28.35M | -25.97M | -26.29M | -100.81M | -149.12M | 42.92M | -185.71M | -102.33M |
| Tax | 77.00K | -291.00K | 345.00K | 411.00K | 63.00K | 2.20M | 1.41M | 939.00K |
| Net profit | -28.43M | -25.68M | -26.64M | -101.22M | -149.19M | 40.72M | -187.12M | -103.27M |
| Basic EPS | -1 | 0 | 0 | -1 | -2 | 1 | -3 | -1 |
| Diluted EPS | -0.59 | -0.41 | -0.41 | -1.42 | -2.10 | 0.54 | -2.57 | -1.41 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 59.55M | 54.76M | 54.32M | 87.24M | 58.59M | 58.89M |
| Gross profit | 31.12M | 26.16M | 28.04M | 57.29M | 29.55M | 32.43M |
| Selling & admin expenses | 36.17M | 35.92M | 31.23M | 33.05M | 34.52M | 32.98M |
| Research & development | 45.84M | 43.14M | 42.76M | 41.40M | 43.82M | 41.00M |
| Operating profit | -50.89M | -52.90M | -45.95M | -17.16M | -48.79M | -41.55M |
| Pretax profit | -59.78M | -42.89M | -32.63M | 32.97M | -59.62M | 7.35M |
| Tax | 28.00K | 287.00K | 162.00K | 462.00K | 408.00K | 1.37M |
| Net profit | -59.81M | -43.17M | -32.80M | 32.51M | -60.03M | 5.98M |
| Basic EPS | -1 | -1 | 0 | 0 | -1 | 0 |
| Diluted EPS | -0.82 | -0.59 | -0.45 | 0.44 | -0.81 | 0.08 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 104.69M | 118.54M | 682.98M | 625.06M | 533.99M | 567.80M | 634.99M | 519.27M |
| Cash & ST investments | 84.07M | 85.83M | 642.69M | 576.48M | 451.09M | 463.00M | 352.12M | 395.46M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 120.73M | 155.27M | 746.26M | 756.49M | 688.59M | 802.96M | 823.23M | 726.16M |
| Total current liabilities | 27.01M | 45.02M | 73.21M | 91.21M | 108.80M | 133.67M | 191.75M | 189.14M |
| Short-term debt | -- | 5.58M | 4.54M | 2.04M | 11.01M | 16.87M | 16.76M | 16.41M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 192,290,000.00 | 248,593,000.00 | 122,244,000.00 | 199,402,000.00 | 240,682,000.00 | 254,397,000.00 | 401,781,000.00 | 362,107,000.00 |
| Total equity | -71.56M | -93.32M | 624.02M | 557.09M | 447.91M | 548.56M | 421.45M | 364.05M |
| Retained earnings | -80.53M | -105.10M | -129.56M | -229.95M | -379.14M | -338.42M | -525.54M | -628.81M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 570.94M | 514.00M | 471.72M | 519.27M | 463.96M | 470.48M |
| Cash & ST investments | 500.30M | 450.19M | 391.23M | 395.46M | 398.96M | 413.74M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 743.03M | 688.24M | 653.66M | 726.16M | 634.19M | 640.39M |
| Total current liabilities | 165.47M | 155.77M | 145.11M | 189.14M | 169.54M | 173.85M |
| Short-term debt | 16.76M | 16.84M | 16.74M | 16.41M | 16.01M | 16.48M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 369,528,000.00 | 345,372,000.00 | 332,308,000.00 | 362,107,000.00 | 320,639,000.00 | 311,438,000.00 |
| Total equity | 373.50M | 342.87M | 321.35M | 364.05M | 313.55M | 328.96M |
| Retained earnings | -585.35M | -628.52M | -661.32M | -628.81M | -688.83M | -682.86M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -23.71M | -26.06M | 16.76M | -70.67M | -119.68M | -136.73M | -157.37M | 13.90M |
| Depreciation & amortization | 2.89M | 3.64M | 3.66M | 2.85M | 4.34M | 5.55M | 6.16M | 6.02M |
| Free cash flow | -28.97M | -27.90M | 14.22M | -77.84M | -127.70M | -150.14M | -164.68M | 12.46M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 896.00K | 0 | 537.09M | -- | 0 | 0 | 8.87M | 0 |
| Ending cash balance | 77.72M | 26.49M | 202.80M | 123.27M | 95.72M | 161.07M | 162.66M | 237.39M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 144.06M | -52.20M | -61.87M | -16.09M | -14.83M | -34.07M |
| Depreciation & amortization | 1.59M | 1.53M | 1.47M | 1.44M | 1.48M | 1.49M |
| Free cash flow | 143.47M | -52.51M | -62.36M | -16.13M | -17.34M | -34.43M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 337.76M | 231.98M | 181.87M | 237.39M | 267.72M | 292.92M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -9.22 | -17.00 | -29.69 | 8.17 | -38.58 | -26.29 |
| ROA %i | -31.80 | -17.81 | -5.43 | -13.36 | -20.65 | 5.46 | -23.01 | -13.33 |
| ROIC %i | -- | -- | -9.38 | -15.90 | -24.84 | 6.56 | -30.78 | -20.40 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -17.26 | -20.68 |
| EBIT margin %i | -41.97 | -45.26 | -56.35 | -80.80 | -81.13 | -81.90 | -100.85 | -65.23 |
| FCF / sales %i | -- | -- | 13.15 | -- | -- | -- | -- | 4.87 |
| Current ratioi | 3.88 | 2.63 | 9.33 | 6.85 | 4.91 | 4.25 | 3.31 | 2.75 |
| Quick ratioi | 3.78 | 2.48 | 9.26 | 6.76 | 4.78 | 4.13 | 3.17 | 2.64 |
| Debt / assetsi | 0.00 | 9.32 | 1.58 | 10.56 | 16.92 | 15.93 | 14.31 | 15.04 |
| LT debt / equityi | -- | -- | 1.16 | 13.97 | 23.55 | 20.24 | 23.98 | 25.50 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | 24.74 | 27.44 | 28.37 | 26.08 | 14.59 | 12.24 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -43.33 | -44.40 | -45.67 | -26.29 | -30.12 | -16.18 |
| ROA %i | -25.96 | -26.34 | -26.61 | -13.33 | -15.03 | -8.18 |
| ROIC %i | -34.04 | -34.37 | -35.12 | -20.40 | -22.74 | -12.15 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -83.63 | -81.09 | -66.34 | -65.23 | -64.65 | -59.24 |
| FCF / sales %i | 9.61 | 10.24 | -- | 4.87 | -- | -- |
| Current ratioi | 3.45 | 3.30 | 3.25 | 2.75 | 2.74 | 2.71 |
| Quick ratioi | 3.30 | 3.13 | 3.09 | 2.64 | 2.64 | 2.62 |
| Debt / assetsi | 15.63 | 16.61 | 17.05 | 15.04 | 16.87 | 16.86 |
| LT debt / equityi | 26.61 | 28.43 | 29.47 | 25.50 | 29.00 | 27.82 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- software is the largest reported line at 60.22% of revenue, across 2 reported segments.
- Drug Discovery follows at 39.78%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
software60.22%
Drug Discovery39.78%
Quote time 2026-10-08 06:53:52 · For reference only, not investment advice and not tailored to your situation.